Suchergebnisse - "EC 1.1.1.41"

PubPharm (7.997)

1

Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors : A multicentric retrospective study

enthalten in: Cancer letters | 2024

von Miele, E. | Anghileri, E. | Calatozzolo, C. | +29

2

Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma : findings from the phase III ClarIDHy study

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Fan, B. | Abou-Alfa, G. | Zhu, A. | +7

3

Intratumoral heterogeneity of CDKN2A deletions in IDH-mutant astrocytoma

enthalten in: Brain tumor pathology | 2024

von Masui, K. | Onizuka, H. | Muragaki, Y. | +3

4

Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia

enthalten in: Blood | 2024

von Leung, W. | Torres Chavez, A. | French-Kim, M. | +10

5

Research Progress of Isocitrate Dehydrogenase Mutation-Positive Acute Myeloid Leukemia --Review

enthalten in: Zhongguo shi yan xue ye xue za zhi | 2024

von Ye, F. | Ma, J.

6

T cells take aim in AML : targeting IDH2

enthalten in: Blood | 2024

von Subklewe, M.

7

Wild-type IDH2 is a therapeutic target for triple-negative breast cancer

enthalten in: Nature communications | 2024

von Li, J. | Yu, T. | Zeng, P. | +9

8

A multi-omics analysis-based model to predict the prognosis of low-grade gliomas

enthalten in: Scientific reports | 2024

von Du, Z. | Jiang, Y. | Yang, Y. | +4

9

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy

enthalten in: Brain tumor pathology | 2024

von Sasaki, H. | Kitamura, Y. | Toda, M. | +2

10

Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation : a network meta-analysis

enthalten in: Journal of chemotherapy (Florence, Italy) | 2024

von Wang, L. | Song, J. | Xiao, X. | +3

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[800]